Monday, March 3rd, 2008
Fresenius Medical Care North America, operator of the nation's leading network of dialysis clinics, announced the opening of Fresenius Medical Care Kapahulu, a new advanced dialysis treatment center. The Medicare-certified facility is located at 750 Palani Avenue, ten minutes from Waikiki Beach. For more information on the clinic, which is ...
Posted in Urology / Nephrology | No Comments »
Monday, March 3rd, 2008
Solvay Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LUVOX® CR (fluvoxamine maleate) Extended-Release Capsules for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adults.
In January 2007, Solvay Pharmaceuticals licensed the right to market LUVOX CR (fluvoxamine maleate) Extended-Release Capsules ...
Posted in Anxiety / Phobias | No Comments »
Monday, March 3rd, 2008
When treating patients with Crohn's disease, early use of an intensive combined immunosuppression (CI) in combination with conventional management is more effective than the current standard, treatment with corticosteroids. These outcomes were reported in an Article in the February 23, 2008 issue of The Lancet.
Crohn's disease is a gastrointestinal disorder ...
Posted in Crohn's | No Comments »
Tuesday, February 26th, 2008
With a four-year, $707,000 grant from the American Cancer Society, Yanchang Wang, assistant professor of biomedical sciences in the Florida State University College of Medicine, hopes to learn how a particular enzyme could possibly help put the brakes on the runaway cell division process that occurs in many forms of ...
Posted in Cancer / Oncology | No Comments »
Monday, February 25th, 2008
Ipsen (Paris:IPN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) provided a positive opinion for Adenuric® (febuxostat) 80 mg and 120 mg tablets for the treatment of chronic hyperuricaemia in gout and recommended it for marketing authorisation. The CHMP recommendation will ...
Posted in Gout | No Comments »
Monday, February 25th, 2008
Repros Therapeutics Inc. (NasdaqGM:RPRX) announced that the Company's Investigational New Drug application for the study of Proellex® in the treatment of anemia associated with uterine fibroids has become effective. The Company will open the IND with two identical registration quality Phase III studies. The work has been awarded to an ...
Posted in Urology / Nephrology | No Comments »
Monday, February 25th, 2008
A delegation from India's Coalition of AIDS Treatment Access (CATA), a diverse group of civil society partners who engage the collective advocacy interests of all the participating members towards better HIV/AIDS treatment, efficient treatment facilities and efficacy in treatment provision for people living with HIV/AIDS throughout India, met on Friday ...
Posted in HIV / AIDS | No Comments »
Saturday, February 23rd, 2008
Merck Serono, a division of Merck KGaA of Germany, has won a Frost & Sullivan Customer Value Enhancement (CVE) Award for its epidermal growth factor receptor (EGFR) targeted therapy Erbitux®, used in the treatment of head and neck (H&N) cancer. The award - for Merck Serono's efforts to provide "unique ...
Posted in Cancer / Oncology | No Comments »
Friday, February 22nd, 2008
The U.S. Food and Drug Administration licensed a treatment for hemophilia A, a rare, hereditary blood-clotting disorder that affects approximately 15,000 individuals, almost exclusively males, in the United States.
The new treatment, called Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free, is a genetically engineered version of factor VIII, a protein essential for ...
Posted in Blood / Hematology | No Comments »
